Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.
Viruses
; 14(5)2022 04 27.
Article
in English
| MEDLINE | ID: covidwho-1810330
ABSTRACT
RNA viruses like SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV) are dependent on host genes for replication. We investigated if probenecid, an FDA-approved and safe urate-lowering drug that inhibits organic anion transporters (OATs) has prophylactic or therapeutic efficacy to inhibit RSV replication in three epithelial cell lines used in RSV studies, i.e., Vero E6 cells, HEp-2 cells, and in primary normal human bronchoepithelial (NHBE) cells, and in BALB/c mice. The studies showed that nanomolar concentrations of all probenecid regimens prevent RSV strain A and B replication in vitro and RSV strain A in vivo, representing a potential prophylactic and chemotherapeutic for RSV.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Syncytial Virus, Human
/
Respiratory Syncytial Virus Infections
/
COVID-19
Limits:
Animals
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
V14050912
Similar
MEDLINE
...
LILACS
LIS